Abstract
In a study of 118 patients with advanced breast cancer treated with aminoglutethimide plus hydrocortisone replacement the overall objective response rate was 42 (36%). Response was not determined either by the nature or the extent of previous treatment, including endocrine therapy and/or chemotherapy, nor by oestrogen-receptor status. The vast majority of patients who responded were postmenopausal but a complete response was seen in a premenopausal patient with skin metastases. Aminoglutethimide is useful in the second-line treatment of postmenopausal subjects with advanced breast cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 107-109 |
Number of pages | 3 |
Journal | South African Medical Journal |
Volume | 72 |
Issue number | 2 |
State | Published - Dec 28 1987 |
ASJC Scopus subject areas
- General Medicine